Aquinox Pharma: Rosiptor Phase 3 Trial Fails To Meet Primary Endpoint

(RTTNews) - Aquinox Pharmaceuticals, Inc. (AQXP) announced that the Phase 3 LEADERSHIP 301 clinical trial evaluating once-daily, oral rosiptor (AQX-1125) for the treatment of interstitial cystitis/bladder pain syndrome failed to meet its primary endpoint. The company said Rosiptor was generally well tolerated with the rate of adverse events during the 12-week treatment period similar to that of placebo and prior trials.

David Main, President and CEO of Aquinox, said: "These results support halting all further development activities with rosiptor. We will be undertaking a thorough evaluation of our pipeline and other strategic options available to the company and will be in a position to provide further guidance later this year."